ABSTRACT
Massive vaccination is one of the most effective epidemic control measures. Because one’s vaccination decision is shaped by social processes (e.g., socioeconomic sorting and social contagion), the pattern of vaccine uptake tends to show strong social and geographical heterogeneity, such as urban-rural divide and clustering. Yet, little is known to what extent and how the vaccination heterogeneity affects the course of outbreaks. Here, leveraging the unprecedented availability of data and computational models produced during the COVID-19 pandemic, we investigate two network effects—the “hub effect” (hubs in the mobility network usually have higher vaccination rates) and the “homophily effect” (neighboring places tend to have similar vaccination rates). Applying Bayesian deep learning and fine-grained simulations for the U.S., we show that stronger homophily leads to more infections while a stronger hub effect results in fewer cases. Our simulation estimates that these effects have a combined net negative impact on the outcome, increasing the total cases by approximately 10% in the U.S. Inspired by these results, we propose a vaccination campaign strategy that targets a small number of regions to further improve the vaccination rate, which can reduce the number of cases by 20% by only vaccinating an additional 1% of the population according to our simulations. Our results suggest that we must examine the interplay between vaccination patterns and mobility networks beyond the overall vaccination rate, and that the government may need to shift policy focus from overall vaccination rates to geographical vaccination heterogeneity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is supported by Purdue Krannert School of Management and MIT Connection Science.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The source data is available from Safegraph https://www.safegraph.com/academics
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
